Symbol | Exchange | Currency |
|---|
Investing.com - Astria Therapeutics (NASDAQ: ATXS) reported first quarter EPS of $-0.720, $0.03 worse than the analyst estimate of $-0.690. Revenue for the quarter came in at $0.00...
Investing.com - Astria Therapeutics reported on Thursday third quarter earnings that missed analysts' forecasts and revenue that was in line with expectations. Astria...
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) announced that it has entered into a partnership with Duchenne UK, a charity to fund its phase II study on the lead pipeline...
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced that the company is expanding its collaboration with CRISPR Therapeutics (NASDAQ:CRSP) for an exclusive licensing...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) announced positive interim data from a phase III study on its duchenne muscular dystrophy (DMD) candidate,casimersen. Data from the...
Astria Therapeutics, Inc. is a biopharmaceutical company focused on discovering, developing and commercialization of therapies to patients and families affected by rare and niche allergic and immunological diseases. The Company’s lead product candidate is STAR-0215, is a potential monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema (HAE). HAE is a rare genetic disorder characterized by severe, recurrent, unpredictable, painful, and sometimes life-threatening swelling in the face, limbs, abdomen and airway. STAR-0215 is a monoclonal antibody inhibitor of plasma kallikrein, which is designed to provide long-acting attack prevention for HAE. The Company’s on-demand treatment of HAE therapy includes BERINERT, FIRAZYR, KALBITOR and RUCONEST. Its long-term preventative treatment of HAE therapy includes CINRYZE, HAEGARDA, TAKHZYRO and ORLADEYO.
| Average | 25.500 (+107.824% Upside) |
| High | 32.000 |
| Low | 20.000 |
| Price | 12.270 |
| No. of Analysts | 6 |
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Buy | Strong Buy | Buy | Sell |
| Technical Indicators | Strong Buy | Strong Buy | Strong Buy | Sell | Strong Buy |
| Summary | Strong Buy | Strong Buy | Strong Buy | Neutral | Neutral |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 190.41 | 192.36 | 187.15 | -1.81 | -0.94% | 115.62M | NASDAQ | |||
| 160.25 | 160.34 | 157.85 | +1.32 | +0.83% | 56.97M | NASDAQ | |||
| 60.90 | 61.01 | 59.91 | +0.98 | +1.64% | 12.65M | NYSE | |||
| 206.01 | 207.58 | 203.55 | +1.73 | +0.85% | 27.63M | NASDAQ | |||
| 105.44 | 105.49 | 103.84 | -0.16 | -0.15% | 30.02M | NASDAQ | |||
| 280.57 | 280.63 | 275.28 | +2.91 | +1.05% | 28.01M | NASDAQ | |||
| 40.39 | 40.46 | 39.87 | +0.21 | +0.52% | 17.13M | NYSE | |||
| 97.95 | 99.52 | 96.74 | -2.33 | -2.32% | 64.14M | NASDAQ | |||
| 98.13 | 98.30 | 96.40 | -0.58 | -0.59% | 55.74M | NASDAQ | |||
| 156.56 | 158.27 | 153.56 | -3.42 | -2.14% | 2.51M | NASDAQ | |||
| 267.79 | 271.67 | 263.55 | -4.12 | -1.52% | 45.08M | NASDAQ | |||
| 8.20 | 8.35 | 8.06 | -0.13 | -1.56% | 17.94M | NYSE | |||
| 106.07 | 106.16 | 104.74 | -0.18 | -0.17% | 25.05M | NASDAQ | |||
| 44.98 | 45.58 | 44.24 | -0.81 | -1.77% | 11.16M | NYSE | |||
| 10.33 | 10.33 | 10.33 | +0.050 | +0.49% | 193.00 | NYSE |